Inventiva (NASDAQ:IVA) Stock Gets Price Target Bump from Truist Financial

Key Points

• Truist Financial raised Inventiva’s price target from $13 to $18 and maintained a “buy” rating, implying approximately 409% upside from the stock’s $3.54 price.
• Analyst sentiment is generally positive: Inventiva has an average “Buy” rating and a consensus price target of $15.86, though Weiss Ratings maintains a “sell” assessment.
• Inventiva reported a quarterly loss of $0.14 per share on $0.75 million in revenue, while its lead candidate, lanifibranor, remains in late-stage development for MASH and related liver disease.

Inventiva (NASDAQ:IVA - Get Free Report) had its price objective boosted by equities research analysts at Truist Financial from $13.00 to $18.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's target price points to a potential upside of 409.05% from the company's current price.

Several other equities research analysts also recently weighed in on IVA. Piper Sandler reissued an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research report on Friday, July 17th. Guggenheim upped their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, September 15th. Finally, Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They set an "overweight" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $15.86.

Inventiva Stock Performance

Shares of NASDAQ:IVA traded up $0.08 during trading on Friday, hitting $3.54. 1,547,517 shares of the company's stock were exchanged, compared to its average volume of 842,853. Inventiva has a 52-week low of $3.11 and a 52-week high of $7.98. The business's 50-day simple moving average is $4.34 and its 200 day simple moving average is $4.67.

Inventiva (NASDAQ:IVA - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The business had revenue of $0.75 million during the quarter. Equities research analysts forecast that Inventiva will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

A number of large investors have recently added to or reduced their stakes in the company. NEXTBio Capital Management LP acquired a new position in Inventiva during the 4th quarter valued at approximately $6,039,000. Propel Bio Management LLC acquired a new position in shares of Inventiva in the 4th quarter valued at about $4,650,000. Eventide Asset Management LLC purchased a new stake in Inventiva in the 4th quarter worth approximately $1,155,000. Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva during the 1st quarter worth approximately $1,111,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Inventiva during the 4th quarter valued at approximately $603,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.